Rivus Pharmaceuticals

Executive Summary

Rivus Pharmaceuticals is a private, clinical-stage biopharmaceutical company focused on developing HU6, an oral small molecule mitochondrial uncoupler designed to achieve sustained, fat-selective, and muscle-preserving weight loss. HU6 targets major unmet needs in obesity, metabolic dysfunction-associated steatohepatitis (MASH), and related cardiometabolic conditions. The drug's unique mechanism differentiates it from GLP-1 receptor agonists by promoting energy expenditure through mild mitochondrial uncoupling, potentially offering an effective and tolerable option for long-term weight management without muscle loss. Rivus is currently advancing HU6 in Phase 2 clinical trials for both obesity and MASH. The company has generated encouraging preclinical and early clinical data showing significant reductions in liver fat and body weight while preserving lean mass, positioning HU6 as a promising candidate in the rapidly growing metabolic disease market. As a privately held company, Rivus relies on venture capital and potential partnerships to fund its development programs. The next 12 months will be critical as the company reports key Phase 2 data that could validate its approach and pave the way for late-stage trials and strategic collaborations.

Upcoming Catalysts (preview)

• Q4 2026HU6 Phase 2 obesity trial top-line data65% success
• H1 2027HU6 Phase 2 MASH trial top-line results60% success
• TBDPotential partnership or licensing deal for HU650% success